• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    BRAF/MEK: Phase II study to test first BRAF combination for metastatic melanoma

    Melanoma has one of the fastest rising rates of human cancer

    BRAF/MEK: The science of targeting one oncogenic pathway

    In theory, it sounds straightforward: Find genetic mutations essential to the growth and survival of the cancer, identify specific inhibitors in the lab, and validate them in human studies

    The future of BRAF inhibitors

    It is daunting for even the most dedicated of scholars to track the alphabet soup of promising molecular targets and pathways

    Forty-one new members join DF/HCC

    Forty-one individuals have recently joined DF/HCC

    Epidemiology pinpoints cancer risk factors and survival strategies

    Some cancers are on the rise, but the overall U.S

    Phase II trial aims to extend ablation to larger liver tumors

    Hepatocellular (HCC) cancer generally has a poor prognosis and, in contrast to other cancers in the United States, mortality is increasing

    CURE program in eighth year of success

    This year, 50 students participated in the CURE program a training opportunity that offers hands-on research experience to high school and college students with the goal of encouraging careers in cancer research

Displaying results 64 to 70 out of 206